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Abstract Studies using an inhibitor of nitric oxide (NO) synthe- 
sis have suggested that endogenous NO may have a role in regu- 
lating endothelin release. We investigated the effect of en- 
dogenous and exogenous nitric oxide (NO) on the release of 
irET-1. L-NAME stimulated, but L-arginine inhibited irET-1 re- 
lease. Perfusing sodium nitroprusside (SNP), however, did not 
inhibit irET-1 secretion. CyelicGMP, the second messenger for 
NO action, was stimulated by SNP but not by L-arginine. These 
data demonstrate that endogenous NO inhibits of irET-1, in a 
manner which is independent of cGMP, and suggest that this 
action may contribute to the vasodilatory effect of NO. 
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1. Introduction 
Nitric oxide (NO) and endothelin-1 (ET-1) are both endothe- 
lium-derived vascular mediators which exert a range of effects 
on different issues, including the adrenal cortex. We and others 
have shown that NO has an important role in the maintenance 
of  adrenal vascular tone, particularly under basal conditions 
[1,2]. It has also been suggested that locally released endothelin 
has a role in the regulation of adrenal function, including ster- 
oidogenesis [3,4]. We have previously demonstrated that ET-1 
is released acutely from the perfused rat adrenal gland in re- 
sponse to changes in perfusion medium flow rate through the 
gland, and that there is a close correlation between flow rate 
and ET-1 release [5]. 
Previous studies investigating interactions between NO and 
ET-1 have demonstrated that one of the effects of endothelin 
is to cause increased NO release [6,7]. It has also been suggested 
that NO may have a role in terminating the response to endo- 
thelin by altering ET receptor-mediated vents [8]. 
While it is well established that cyclicGMP-dependent vaso- 
dilators may influence ET-1 release, much of the research effort 
has concentrated on the use of cGMP analogues and atrial 
natriuretic peptides, and there has been little attention paid to 
NO, which also stimulates cGMP. Some studies have addressed 
the role of NO by using inhibitors of nitric oxide synthase, the 
enzyme responsible for NO production, and in general have 
shown that inhibition of this enzyme results in increased ET-1 
release [9,10]. As far as we are aware, no studies have deter- 
mined the effect of stimulating endogenous NO production on 
the release of ET-1. 
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The present study was designed to directly investigate the 
role of NO in regulating ET-1 release from the intact perfused 
rat adrenal preparation. This experimental pproach is ideally 
suited to the study of vascular effects and vascular mediators, 
and has been used to investigate various aspects of adrenal 
vascular function and ET-1 release [3,11]. In the present study 
we have used the perfused adrenal preparation to investigate 
the effects of endogenous NO on release of ET-1. Two ap- 
proaches have been used: first perfusing with an k-arginine free 
medium, supplemented with various concentrations of L-argin- 
ine and second, by infusing E-NAME, an inhibitor of NO syn- 
thase, in the presence of L-arginine. In addition we have inves- 
tigated the effects of exogenous NO by perfusing with an NO 
donor, sodium nitroprusside. 
As previous studies have mainly concentrated on relating 
cGMP to ET-1 release, the secretion of cGMP was also deter- 
mined in some of the experiments described. 
2. Materials and methods 
All chemicals were obtained from Sigma, Poole, Dorset, UK, except 
for the high sensitivity endothelin assay kits and the cGMP assay kits 
which were purchased from Amersham International p c, Amersham, 
Bucks UK. Male Wistar rats, body weight 250 350 g, obtained from 
Charles River, Margate, Kent, UK were maintained at Queen Mary 
and Westfield College for a minimum of 5 days prior to use. They were 
fed standard rat chow and water was available ad libitum. Animals were 
anaesthetised with urethane (140 mg/kg i.p.) before surgery and 100 U 
heparin was administered via a cannula in the jugular vein. 
The method for perfusing the intact rat adrenal gland in situ has been 
described in detail elsewhere [12,13]. Briefly, perfusion medium was 
introduced, via the coeliac artery, into an isolated segment of aorta, 
from which the adrenal arteries arise. After passing through the adrenal 
the perfusate was collected from a pocket in the renal vein. Once all the 
ligatures are in place, and the perfusion is established, the animal is 
killed with an overdose of urethane into the jugular cannula, and there- 
after is used only as a platform for the adrenal gland, which remains 
in situ. 
The perfusion medium was either Hank's Balanced Salt Solution 
(HBSS) which contains no L-arginine, or Tissue Culture Medium 199 
(TC199) which contains e-arginine. Both media have a potassium ion 
concentration appropriate to the human, and in order to adapt these 
media for use in the rat, were modified by dilution (4 : 3) with KCl-free 
Krebs bicarbonate Ringer, to give a final potassium ion concentration 
of 3.9 mmol/k approximating to the normal concentration of this ion 
in the rat. Bovine serum albumin was added to the perfusion medium 
(0.5 g/100 ml). 
In some experiments either sodium nitroprusside or k-arginine was 
added to HBSS. The final L-arginine concentration i the modified 
TC199 was 230 ¢tmol/l. The perfusion medium was continuously gassed 
with 95% 02/5% CO2 and delivered at a constant rate of 0.6 ml/min. 
This is an isolated perfusion preparation and thus the gland receives 
only the perfusion medium supplied. The gland remains in situ, how- 
ever, and is supplied by the orthograde route through the normal 
vasculature. Although the gland only receives perfusion medium, sup- 
plied at a constant rate, not all the medium supplied passes through the 
gland: some is dispersed through adjacent arterioles. In this way the 
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preparation is able to respond to changes in vascular esistance within 
the gland: a decrease in vascular esistance causes an increase in the 
proportion of the medium supplied passing through the gland. This is 
monitored by measuring the volume of perfusion medium collected 
over a ten-minute period. Under basal conditions approximately 30% 
of the medium supplied passes through the gland. After an initial 
equilibration period of 40 min, four 10-min control samples were col- 
lected. After this control period the experimental procedures were car- 
ried out. In some experiments flow rate through the gland was increased 
mechanically by increasing the rate of delivery of perfusion medium. 
In other experiments L-NAME, L-arginine or its enantiomer D-arginine 
was infused. 10-min samples were collected on ice in plastic tubes 
throughout the experiment. The volume of each sample collected was 
recorded and an aliquot aken for ET-1 and cGMP assay. Samples were 
immediately frozen and stored at -70°C for up to one week prior to 
assay. 
2.1. Statistical analysis 
Data were expressed as percentage change from control. Results 
given are the mean percent change from several experiments + S.E.M. 
Statistical analysis of the data was performed using Student's paired 
t-test, or analysis of variance, as appropriate. 
3. Results 
Supplementing HBSS with sodium nitroprusside caused an 
increase in perfusion medium flow rate through the perfused 
adrenal gland (Fig. 1), which was accompanied by an increase 
in immunoreactive ET-1 (irET-l) release (Fig. 2). The addition 
of k-arginine to HBSS also caused an increase in flow rate but 
a decrease in irET-1 secretion (Figs. 1 and 2). 
In experiments where the rate of delivery of perfusion me- 
dium was altered mechanically, there was a significant correla- 
tion between flow rate and irET-1 secretion under all condi- 
tions used. Addition of L-arginine, the substrate for en- 
dogenous NO production, to HBSS caused a significant de- 
crease in the secretion rate ofirET-1 (Fig. 3). In addition, when 
TC199 was used as perfusion medium (containing 230 ¢tmol/I 
L-arginine) a lower rate of irET-1 release was observed corn- 
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Fig. 1. Percentage increase in perfusion medium flow rate through the 
intact perfused rat adrenal gland seen by adding either L-arginine or 
sodium nitroprusside (SNP) to HBSS perfusion medium. Values are 
mean + S.E.M. Numbers of experiments are indicated in the bars. 
*P < 0.05, **P < 0.01, ***P < 0.001 compared to basal evels obtained 
with HBSS alone (analysis of variance). 
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Fig. 2. Effects of adding either L-arginine or sodium nitroprusside 
(SNP) to HPSS perfusion medium on the release of immunoreactive 
ET-1 from the perfused rat adrenal gland. Values are mean _+ S.E.M. 
Numbers of experiments are indicated in the bars. *P< 0.05, 
**P < 0.01, compared to basal evels obtained with HBSS alone (anal- 
ysis of variance). 
pared to experiments where HBSS was used (Figs. 3 and 4). 
Addition of L-NAME to perfusion medium TC199 caused a 
marked increase in the release of irET-1 (Fig. 4). A summary 
of the effects of altered endogenous NO production on irET-1 
release is given in Table 1. 
The effects of perfusing with HBSS supplemented with L- 
arginine and sodium nitroprusside on cGMP release from the 
perfused adrenal are shown in Fig. 5. While sodium nitroprus- 
side caused a significant stimulation of cGMP release, addition 
of L-arginine to the perfusion medium significantly attenuated 
cGMP release. The mean basal rate of cGMP secretion was 
550 + 120 fmol/10 rain. D-Arginine had no effect on any of the 
parameters measured (data not shown). 
4. Discussion 
The data obtained in the present study, using an intact per- 
fused adrenal gland preparation, demonstrate for the first time 
that ET-1 release is enhanced in the absence of endogenous NO 
production, inhibited by endogenous NO, but not affected by 
the addition of an exogenous NO donor. As most of the exper- 
imental studies on endothelial cell function have employed cul- 
tured endothelial cells it is difficult to draw direct comparisons 
between data obtained in this way, and data obtained from an 
in situ perfusion preparation. 
This is the first study, as far as we are aware, which has 
demonstrated a relationship between NO synthesis and irET-I 
release under a variety of different conditions. Previous studies 
have almost exclusively employed inhibitors of NO synthesis, 
including L-NAME, and have demonstrated conflicting results, 
largely depending on the preparation and the stimulus used. 
Hishikawa and co-workers [14], using cultured endothelial 
cells, found that the elevated ET-1 secretion seen in response 
to increased pressure was unaffected by an inhibitor of NO 
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Fig. 3. Effects of perfusing with Hanks balanced salt solution in the 
presence (o) and absence (o) of e-arginine (1 mmol/1) on the correlation 
between perfusion medium flow rate and irET-1 release by the intact 
perfused rat adrenal gland. In each case a highly significant correlation 
was seen: HBSS alone r = 0.82, P < 0.00h with L-arginine r = 0.83, 
P < 0.001. 
synthesis. On the other hand, Boulanger and Luscher [9], using 
porcine arteries in vitro, found that thrombin-stimulated ET-1 
release was enhanced in the presence of an NO synthesis inhib- 
itor, although basal release was unaffected. Cao and co-work- 
ers [15] also found that L-NAME increased the ET-1 concentra- 
tion, measured in the femoral artery of dogs, in response to 
hypoxia. The present study appears to be the first in which the 
effects of c-arginine, the substrate for NO synthesis, were inves- 
tigated. Some other studies have infused e-arginine into human 
subjects and measured an increase in e-citrulline production, 
the by-product of NO synthase activity [16]. Presumably the 
subjects were not e-arginine deficient, but it was, nevertheleses 
possible to stimulate NO synthase activity simply by increasing 
substrate levels. In the present study, in the experiments using 
HBSS, the perfusion medium used did not contain L-arginine 
for the first hour of the perfusion, and thus cellular stores of 
L-arginine are likely to have been exhausted during this time. 
The change from L-arginine free medium to L-arginine supple- 
mented medium is likely to cause an increase in NOS activity 
Table 1 
Effect of endogenous NO production on irET-1 release per ml perfu- 
sion medium collected. 
irET-1 fmol/ml perfusate 
HBSS 28.2 + 1.0 n = 20 
HBSS + 1 mmol/1 L-arginine 13.1 + 0.65*** n = 22 
TC199 11.5 + 0.31"** n = 28 
TC199 + 5 mmol/l L-NAME 28.2 + 3.0 n#~ n -- 12 
HBSS contains no L-arginine, TC199 contains 230/lmol/1 L-arginine 
and L-NAME is an inhibitor of NO synthase. Values are 
mean + S.E.M. ***Indicates value significantly (P < 0.001) different 
from HBSS alone. #n#Indicates value significantly (P < 0.001) different 
from TC199 alone. Student's t-test. 
in this preparation. Therefore it is likely that the effects seen 
are the result of increased NOS activity. 
Different effects of inhibiting NO synthase activity on ET-1 
release have been reported depending on whether ET-1 release 
is basal or stimulated. It is difficult to determine whether the 
effects reported here should be considered to be effects on basal 
or stimulated ET-1 release. The addition of L-arginine or so- 
dium nitroprusside to the perfusion medium caused an increase 
in perfusion medium flow, and it can be assumed that this 
results in the adrenal endothelial cells being exposed to an 
increased shear stress. While it has been reported that ET-I 
release is stimulated by shear stress [17], this holds true only for 
low levels of shear stress, with moderate or elevated shear 
inhibiting ET-1 release while stimulating NO [18]. As we have 
demonstrated a direct correlation between flow rate through 
the adrenal gland and irET-1 release it is unlikely that the shear 
stress generated in these experiments is significantly inhibiting 
ET-1 release. We have previously shown that the addition of 
L-NAME to the perfusion medium causes a significant decrease 
in flow rate through the gland [1], and is therefore unlikely to 
alter ET-1 release in this preparation as a direct result of flow 
rate changes. It is therefore likely that the effects of changes in 
NO synthesis on ET-1 release reported here reflect changes in 
'basal' rates of release. ET-1 is known to be a potent vasocon- 
strictor: these data suggest hat inhibition of basal ET-1 release 
may be a component of the vasodilatory effect of NO. 
It is possible that higher NO concentrations in endothelial 
cells would been achieved by stimulating endogenous produc- 
tion, and this may account for the differences een. This seems 
unlikely, however, as sodium nitroprusside was more effective 
in stimulating cGMP release than was k-arginine. Clearly the 
inhibition of endothelin release observed in this study was un- 
likely to be a result of increased cGMP production as e-arginine 
inhibited both cGMP and ET-1 release, and sodium nitroprus- 
180 
160 
o 
"~ 140 
fi 
z 120 
,--1 
::= 100 
0 
z 80  
ET3 
6O 
:~ 40 - 
0 
Z 
2O 
0 
E3 
/, 
/ 
/ 
/ 
/ /- 
/ /  
/ 
/ 
/ 
- [3[2 
/ -  
[] m ~ - ~  - 
0 1 2 3 4 
FLOW RATE (ml ,  lOmin)  
Fig. 4. Effects of perfusing with Tissue Culture Medium 199 in the 
presence or absence of L-NAME on the correlation between perfusion 
medium flow rate and irET-1 release by the intact perfused rat adrenal 
gland. In both cases a highly significant correlation was seen. TC199 
alone (m) r = 0.93, P < 0.001; L-NAME ([]) r = 0.77, P < 0.001. 
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Fig. 5. Effects of adding either L-arginine or sodium nitroprusside 
(SNP) to HBSS perfusion medium on the release of cyclicGMP from 
the perfused rat adrenal gland. Values are mean _+ S.E.M. Numbers of 
experiments are indicated in the bars. *P<0.05, **P<0.01, 
***P < 0.001 compared to basal levels obtained with HBSS alone, 
(analysis of variance). 
side, while stimulating cGMP, did not cause inhibition of ET- 1 
release. Several studies have investigated the effects of altered 
cGMP production on ET-1 release and have shown that cGMP 
inhibits ET-1 release. While NO is known to stimulate cGMP 
production, this action is shared by the natriuretic peptides, 
which have also been shown to inhibit ET-1 release [19]. An 
effect of inhibitors of cGMP production on ET-1 release can 
only therefore be considered as indirect evidence for a role of 
NO in ET-I release. It appears that ET-1 release in this perfu- 
sion preparation is not controlled by cGMP in the same manner 
as in the experimental preparations used in other studies. 
The question then arises as to the mechanism of the effects 
reported in the present study: as both L-NAME and L-arginine 
were used to manipulate ndogenous NO production, the ef- 
fects seen are unlikely to be as a result of a non-specific toxic 
action of these agents, particularly as I>arginine was without 
effect. Rather, the effects seen may be due, either to an action 
of NO which is not mediated by cGMP, or alternatively, an- 
other product of NOS activity may be implicated, possibly 
citrulline. This possibility awaits investigation. 
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